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Age-Dependent Disease Expression Determines Remodeling of the
Retinal Mosaic in Carriers of RPGR Exon ORFn15 Mutations
Abstract
PURPOSE. To characterize the retinal histopathology in carriers of X-linked progressive retinal atrophy
(XLPRA1 and XLPRA2), two canine models of X-linked retinitis pigmentosa caused, respectively, by a stop
and a frameshift mutation in RPGRORF15.
METHODS. Retinas of XLPRA2 and XLPRA1 carriers of different ages were processed for morphologic
evaluation, TUNEL assay, and immunohistochemistry. Cell-specific markers were used to examine retinal
remodeling events.
RESULTS. A mosaic pattern composed of patches of diseased and normal retina was first detected in XLPRA2
carriers at 4.9 weeks of age. A peak of photoreceptor cell death led to focal rod loss; however, in these patches
an increased density of cones was found to persist over time. Patches of disease gradually disappeared so that
by 39 weeks of age the overall retinal morphology, albeit thinner, had improved lamination. In older XLPRA2
carriers (≥8.8 years), extended regions of severe degeneration occurred in the peripheral/mid-peripheral
retina. In XLPRA1 carriers, opsin mislocalization and rare events of rod death were detected by TUNEL assay
at 20 weeks of age; however, only patchy degeneration was seen by 1.4 years and was still apparent at 7.8 years.
CONCLUSIONS. The time of onset and the progression of the disease differed between the two models. In
the early-onset form (XLPRA2) the morphologic appearance of the retinal mosaic changed as a function of
age, suggesting that structural plasticity persists in the early postnatal canine retina as mutant photoreceptors
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Abstract
Purpose—To characterize the retinal histopathology in carriers of X-linked progressive retinal
atrophy (XLPRA1 & XLPRA2), two canine models of X-linked retinitis pigmentosa caused,
respectively, by a stop and a frameshift mutation in RPGRORF15.
Methods—Retinas of XLPRA2 and XLPRA1 carriers of different ages were processed for
morphologic evaluation, TUNEL assay, and immunohistochemistry. Cell-specific markers were used
to examine retinal remodeling events.
Results—A mosaic pattern composed of patches of diseased and normal retina was first detected
in XLPRA2 carriers at 4.9 weeks of age. A peak of photoreceptor cell death led to focal rod loss;
however, in these patches an increased density of cones was found to persist over time. Patches of
disease gradually disappeared such that by 39 weeks of age the overall retinal morphology, albeit
thinner, had improved lamination. In older XLPRA2 carriers (≥8.8 years), extended regions of severe
degeneration occurred in the peripheral/mid-peripheral retina.
In XLPRA1 carriers, opsin mislocalization and rare events of rod death were detected by TUNEL
assay at 20 weeks of age, however patchy degeneration was only seen by 1.4 years, and was still
apparent at 7.8 years.
Conclusion—The time of onset and the progression of the disease differed between the two models.
In the early onset form (XLPRA2) the morphologic appearance of the retinal mosaic changed as a
function of age, suggesting that structural plasticity persists in the early postnatal canine retina as
mutant photoreceptors die. In the late onset form (XLPRA1), patches of disease persisted until later
ages.
INTRODUCTION
X-linked retinitis pigmentosa (XLRP) comprises some of the most severe forms of RP, and
accounts for about 10–20% of familial cases.1, 2 Six loci (RP2, RP3, RP6, RP23, RP24, RP34)
have been associated by linkage analysis with XLRP; of these RP2 and RP3 are the two most
common (www.retnet.org). Retinitis pigmentosa GTPase regulator (RPGR), the disease gene
of the RP3 locus, accounts for > 70 % of the cases of X-linked retinitis pigmentosa (XLRP),
3–6 and exon ORF15, a mutational hot spot in RPGR, was shown to be mutated in 22–60% of
XLRP patients.3, 7, 8
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Mutations in RPGR can cause a spectrum of retinal diseases that include cone-rod dystrophies,
9 macular degeneration,10 and more commonly rod cone degenerations.11 Males affected with
RPGR-XLRP typically exhibit night blindness in their first decade of life followed by reduction
of their visual field, and loss of central visual acuity. By the end of their fourth decade most
patients are legally blind.12 Female carriers, on the other hand, display a broad spectrum of
disease severity. The age of onset and the extent of fundus pigmentary changes, visual field
defects and ERG abnormalities vary considerably between and within families.11, 13–15 A
characteristic of female XLRP carriers is the patchy nature of the disease expression when
assessed by funduscopic examination, Goldmann perimetry11, 16, multifocal ERG17, and
histopathology 16, 18–20. This mosaic of normal and diseased retinal foci is best explained by
Lyon’s hypothesis of random X-chromosome inactivation that occurs at an early stage of
female embryogenesis.21
Histopathological reports of the retinal lesions in XLRP carriers are scarce. Indeed, they are
limited to that of four individuals, three of them carrying mutations in RPGR.16, 18–20 Since
these studies were conducted on postmortem retinas of older (> 75 years of age) patients, the
findings represent histological alterations observed at an advanced stage of disease. For
obvious reasons, access to retinal tissues from younger patients is likely to be even more
limited, and currently hampers our understanding of the course of disease in XLRP carriers.
The use of animal models with naturally occurring forms of X-linked retinal degeneration
represents a valuable tool to examine whether in carriers the mosaic pattern of degenerate and
normal retinal foci remains unchanged throughout the course of disease, or whether remodeling
of these patches takes place.
In the dog, two distinct forms of X-linked retinal degeneration, termed XLPRA1 and
XLPRA2, have been characterized, and are caused, respectively, by a stop and a frameshift
mutation in RPGR exon ORF15.22. The frameshift mutation causes an early and severe loss of
photoreceptors (XLPRA2) that begins a few weeks after birth, while the stop mutation disease
(XLPRA1) has a later onset (~11 months of age), and more gradual progression.22–24 In both
diseases, multiple patches of degeneration have been reported in carriers.22, 24 In the current
study, we have expanded the analysis of the retinal mosaic in XLPRA1 and XLPRA2
heterozygotes, and find focal lesions of photoreceptor disease and degeneration similar to those
observed throughout the retinas of homozygotes. In addition, we report that the retinal mosaic
disease pattern changes as a function of age in XLPRA2 carriers, while no such retinal plasticity
occurs in carriers of the later onset XLPRA1 disease.
MATERIALS and METHODS
Animals
Twelve dogs were used for this study. This included 10 crossbred female XLPRA2 carrier dogs
(age range: 3.9 weeks to 10.3 years), and 2 crossbred female XLPRA1 carrier dogs (age: 20
and 24 weeks). All dogs were bred at the Retinal Disease Studies Facility (RDSF, University
of Pennsylvania, New Bolton Center, Kennett Square, PA), and their genotype was determined
either from the known status of their progenitors, or from genetic testing for the disease-causing
mutation.22 All animals were anesthetized by intravenous injection of sodium pentobarbital,
enucleated, and then euthanatized. All procedures involving animals were done in compliance
with the ARVO Statement for the Use of Animals in Ophthalmic and Vision Research. In
addition to the 12 dogs that were specifically bred for this study, archival retinal sections from
7 older carriers of XLPRA1 (age range: 1.4 years – 7.8 years) were included (Table1). No
experiments with tissues from wild-type (i.e. non-mutant) dogs were repeated in the current
study as they had already been performed and reported in a previous publication.23
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Retinal histology
The left eyes of 8 XLPRA2 carrier dogs (age range: 3.9 weeks – 10.3 years) were used for
morphologic examination of disease expression using plastic or OCT embedding (see Table
1: morphology). Tissues were processed for plastic embedding as previously reported, and
using a similar protocol as for the archival tissues from the 7 XLPRA1 carriers.25 After
enucleation, the globes, and then the posterior segments, were isolated and fixed following a
sequential triple fixative protocol (3% glutaraldehyde-2% formaldehyde; 2%
glutaraldehyde-1% osmium tetroxide; and 2% osmium tetroxide). The posterior segments were
then trimmed into pieces that extended from the optic nerve head to the ora serrata along the
superior and inferior meridians, dehydrated, and embedded in epoxy resin (PolyBed 812,
Polysciences, Warrington, PA). Tissues were sectioned with glass knives at 1 μm with a 2065
Reichert Jung supercut microtome (Leica, Deerfield, IL), stained with azure II-methylene blue
with or without a paraphenylenediamine (PPDA) counterstain.
Sections from both the superior and inferior meridians were examined with a 40X objective
by light microscopy (Axioplan; Carl Zeiss Meditech, Oberkochen, Germany). The sections
were examined in contiguous fields from the optic disc to the ora serrata. This included
evaluation of the retinal pigment epithelium (RPE), the rod and cone outer (OS) and inner (IS)
segments, the thickness and density of the outer nuclear and inner nuclear layers (ONL & INL).
Quantitative measurements of the ONL were made in XLPRA2 carriers in the central (site S1:
2,000 ± 500 μm from the optic nerve head), peripheral (site S3: 2,000 ± 500 μm from the ora
serrata), and mid-peripheral (site S2: midpoint ± 500 μm between the optic nerve head and
the ora serrata) regions. As most archival sections from the XLPRA1 carriers did not contain
either the optic nerve head or the ora serrata, the measurements were made at the extremities
of the section and referred to as central and peripheral retina.
TUNEL assay
In 8 XLPRA2 and 2 XLPRA1 carrier dogs, one eye was processed to perform TUNEL assays
and/or immunohistochemistry (Table 1: TUNEL, IHC). Following enucleation, a slit was made
through the globe at the level of the ora serrata, and the entire globe was fixed in
paraformaldehyde, cryoprotected, and embedded in optimal cutting temperature (OCT)
medium as previously reported.23
Cryosections (7 μm thick) along the superior meridian were used for TUNEL assay following
the manufacturer’s protocol (In situ cell death detection kit, Roche, Indianapolis, IN), and
stained with DAPI. Positive controls included sections pretreated with DNAse I (3 U/ml in 50
mM Tris-HCl, pH 7.5, 1 mg/ml BSA for 10 min at room temperature). For negative controls
the terminal transferase enzyme was omitted from the TUNEL reaction mixture. Sections were
examined from the optic disc to the ora serrata by epifluorescence microscopy with the 40X
objective. TUNEL-labeled cells in the ONL were counted throughout the entire length of the
section, i.e. from disc to ora serrata. In order to determine the proportion of photoreceptor
cells that undergo cell death as a function of time, we expressed our results as the number of
TUNEL-labeled photoreceptor cells per 106 μm2 of ONL as previously reported.23 The area
of the ONL of each section was obtained by measuring the entire length of the ONL from optic
disc to ora serrata, and multiplying it by the average thickness of the ONL throughout the
section (mean value of the thickness measured in the 3 locations reported above). If focal
thinning was present at the site, the closest adjacent site that was representative for the ONL
thickness was measured. In areas of decreased photoreceptor density this method may slightly
underestimate the proportion of cells that are TUNEL positive, but was selected because
individual cell counts could not be determined on 7 μm thick DAPI stained cryosections. For
each dog, this was done in triplicate with sequential sections from the superior meridian. The
values were averaged and reported as mean ± SD.
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Immunohistochemistry
Cryosections made along the superior retinal meridian of 8 XLPRA2 and 2 XLPRA1 carrier
dogs were processed as described above and were used for fluorescent IHC. We used a battery
of cell-specific antibodies, most of which already have been shown to specifically label the
canine retina (see details in Table 2).23 Since previous testing of RPGR and RPGRIP antibodies
conducted in our laboratory failed to show any crossreactivity or specificity on dog retina, we
did not include them in this study.22 Cryosections (7–10 μm thick) were incubated overnight
with the primary antibodies following a blocking step with 10% normal serum from the
appropriate species. The antigen-antibody complexes were visualized with fluorochrome-
labeled secondary antibodies (Alexa Fluor, 1:200; Molecular Probes, Eugene, OR). DAPI stain
was used to detect cell nuclei. Slides were mounted with gelvatol, a medium composed of
polyvinyl alcohol and DABCO (Sigma-Aldrich, St Louis, MO), and examined with an
epifluorescent microscope (Axioplan). Images were digitally captured (Spot 4.0 camera), and
imported into a graphics program (Photoshop; Adobe, Mountain View, CA) for display.
Confocal microscopy was also used on a subset of sections to image discrete structural changes
occurring in the outer segments. Confocal images were acquired on a Leica TCS-SP5 tunable
confocal and MP system with a Leica DM 6000 CFS upright microscope (Leica Microsystems,
Wetzlar, Germany) through a 40x oil lens (N.A. = 1.25). The specimens were excited at 488
nm supplied by an Argon laser. DAPI was excited with multi-photon at 720 nm produced by
a Coherent Chameleon Ultra II Ti:sapphire pulse laser (Santa Clara, CA, USA ).
RESULTS
Multifocal retinal degeneration
Retinal histopathology of XLPRA2 carriers—At 3.9 weeks of age, no morphologic
abnormalities could be seen in the maturing photoreceptors (Figure 1 A). The earliest
alterations that could be detected by 4.9 weeks of age on 1 μm-thick plastic sections consisted
in patchy areas of OS misalignment and disruption resulting in a weaker PPDA staining (Figure
1 B); occasional pyknotic nuclei also were seen. At 5.9 weeks, there was more prominent OS
disorganization that resulted in a clearer demarcation between diseased and non-diseased foci
(Figure 1 C). In diseased areas, rod cell density was decreased, yet consistently there was an
increase in ONL thickness due to increase in inter-nuclear distance. By 26.1 weeks of age
(Figure 1 D1), there was a generalized thinning of the ONL. Patches of disease surrounded by
structurally normal retina persisted, but they appeared to be fewer and of smaller size (Figure
1 D2,3). This was even more obvious by 39 weeks of age. In older dogs (8.8 and 10.3 years)
multifocal patches were rarely found, but end stage peripheral retinal atrophy that extended
towards the mid-peripheral region was observed (Table 3). Differences were observed between
the two aged dogs both in the location and the extent of the retinal damage. In the 8.8 year-old
dog, severe peripheral retinal damage (total atrophy to 1–2 rows of nuclei in the ONL) was
seen in the superior region extending up to 7,000 μm from the ora serrata. The central retina
had a thin ONL (4 rows of nuclei), photoreceptors had enlarged and short IS, but maintained
their OS. Inferiorly, severe retinal damage (0–2 rows of nuclei) was seen throughout the entire
retinal section. No OS were visible inferiorly, and the RPE was either directly apposed to the
external limiting membrane (ELM) or to shortened IS. In the 10.3 year-old dog the peripheral
and mid-peripheral regions of the retina were also severely affected, yet photoreceptor loss
was more prominent superiorly than inferiorly (Figure 1 E1–3).
Retinal histopathology of XLPRA1 carriers—Examination of H&E stained
cryosections from a 20 and 24 week-old XLPRA1 carrier did not reveal any morphologic
alterations compatible with an ongoing disease process (Figure 2 A1–3). The earliest age at
which foci of disease were found was at the next time point, 1.4 years. These were observed
throughout the retinal length and characterized by a local loss of OS, and a decrease in rod
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density and ONL thickness (Figure 2 B1–3). Beginning at 4.9 years of age and increasing with
time, foci of increased cone density and rod loss were seen throughout the retina length (Figure
2 C1–3). Similarly to that reported in affected animals,24 substantial differences in disease
severity were observed between carrier dogs of similar ages (e.g. dogs H6 and H74, see Table
4).
Immunohistochemical characterization of retinal disease in XLPRA carriers
Multifocal retinal disease in XLPRA2 carriers—Cell specific markers for rods and
cones were tested to determine whether they were differentially expressed in normal and
diseased areas of the retina (Figure 3). Immunolabeling with rod opsin revealed alterations as
early as 3.9 weeks of age that were similar to that previously reported in affected animals. 23
These consisted of rod opsin mislocalization to the IS and ONL, and rod neurite sprouting
(Figure 3 A1). However in the case of the carrier dogs examined in this study, these
abnormalities had a multifocal distribution that overlapped with the areas of ONL thickening.
DAPI labeling confirmed that areas of increased ONL thickness corresponded to areas of
diseased rods (Figure 3 A2). At 39 weeks of age the number of patches of rod opsin
mislocalization and ONL thickening were considerably reduced (Fig 3 B1–2). By confocal
microscopy we also confirmed that in those regions where opsin was mislocalized, and the
ONL thickened, rod OS were misaligned and disorganized (Fig 3 C1–2).
Since cone opsins have been shown to mislocalize during the early phase of the disease in
affected XLPRA2 dogs we investigated whether this also occurred in carriers (Figure 4). Double
immunolabeling with rod opsin and M/L opsin antibodies showed mislocalization of M/L cone
opsin in young animals (3.9 – 12 weeks of age) in the same retinal patches where rod opsin
was mislocalized (Figure 4 A1–2). A peculiar finding that could be detected as early as 5.9
weeks of age was the increased density of M/L cones in the patches where rod opsin was
mislocalized (Figure 4 C1–3) A similar observation was made when labeling cones with human
cone arrestin antibody (data not shown). In older animals (39 weeks), patches of M/L opsin
mislocalization persisted despite a decrease in rod opsin mislocalization. Thus, there were
fewer patches of rod opsin mislocalization than patches of M/L cone opsin mislocalization
(data not shown), suggesting a possible loss of mutant rods and the persistence of diseased
cones. The temporal pattern of S opsin labeling was slightly different since mislocalization,
which also occurred in the areas where rod opsin mislocalized (Figure 4 B1–2), was rarely seen
after 12 weeks of age. No clumping of S cones was seen as with M/L cones. This was not
surprising since there as fewer S cones than M/L cones in the canine retina.
At 26.1 weeks of age, phagocytic cells were frequently seen in the subretinal space of the
degenerating patches, but not in the surrounding intact areas. Double immunolabeling with
RPE65 and CD18 antibodies demonstrated that these cells were macrophages rather that
detached RPE cells migrating into subretinal space. (Figure 5 A, B)
Because photoreceptor degeneration in affected XLPRA2 dogs is associated with inner retinal
remodeling, we investigated whether focal retinal disease altered the underlying inner retina
in XLPRA2 carriers. PKCα and Goα labeling showed a retraction of the dendrites of rod bipolar
cells that synapse with the diseased rods. (Figure 6 A1, asterisks). GABA IHC, which was used
to label GABAergic amacrine cells as well as the inner plexiform layer (IPL), did not show
any focal alterations in the areas of photoreceptor disease in either young or older animals (data
not shown). Müller cell reactivity, which was evidenced by intense GFAP labeling, occurred
in the patches of photoreceptor disease as early as 8 weeks of age, and was still intense at 12
weeks (Figure 6 B1–2). At 26.1 weeks of age, radial extensions of GFAP labeling were
considerably reduced, and by 39 weeks labeling was limited to astrocytes, and Müller cell end
feet in the nerve fiber layer (data not shown).
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Multifocal retinal disease in XLPRA1 carriers
IHC experiments were limited to the two dogs (20 and 24 weeks old) that had their retinas
embedded in OCT. A patchy pattern of rod opsin and M/L cone opsin mislocalization was seen
at both ages (Figure 7). Although rod neurite sprouting was clearly visible, we did not observe
a thickening of the ONL at the sites of disease as in the XLPRA2 carriers. It is important to
note that mislocalization of rod and M/L cone opsins occurred at an age when there are no
structural abnormalities visible in the retina by light and electron microscopy in hemizygous
males.24 S opsin mislocalization was seen in both animals but was limited to the peripheral
retina (data not shown). No abnormal pattern in PKCα or Goα labeling was observed either,
and GFAP labeling was limited to astrocytes and Müller cell end feet (data not shown).
Kinetics of photoreceptor cell death
TUNEL assay was performed on XLPRA2 carrier retinas to determine the course of
photoreceptor cell death. Quantification of TUNEL-labeled photoreceptors in XLPRA2 carriers
showed a similar burst of cell death at 5.9 weeks of age (241–302 TUNEL-labeled cells per
106 μm2 of ONL) as previously reported in affected XLPRA2 dogs (Figure 8 A and 23). Between
12 and 26.1 weeks of age, there was a significantly reduced and more constant rate of cell
death. By 39 weeks of age only 2–8 TUNEL-labeled cells per 106 μm2 of ONL were counted.
To confirm that cell death was occurring within the foci of retinal disease, we examined sections
that were TUNEL-labeled and processed for rod opsin IHC. Results showed that TUNEL-
positive photoreceptors were only found in areas where rod opsin was mislocalized to the ONL
(Figure 8B). In the 20 and 24 week-old XLPRA1 carriers, a limited number of TUNEL-labeled
rods were observed and were restricted to the foci of rod opsin mislocalization (Figure 8 C).
Remodeling of the retinal mosaic in XLPRA2 carriers
Evident thinning of the ONL was seen in older carriers of XLPRA2, and, in addition, there also
seemed to be fewer disease patches (Figure 9). To further substantiate the observation that the
retinal mosaic appeared to remodel in the young adult dog, we determined the proportion of
retinal length that was occupied by foci of retinal degeneration as a function of age. This was
done, when possible, on sections from both the superior and inferior meridians. Our findings
(Figure 9 A1–2, B) show that at 5.9 weeks of age, large and numerous foci of disease occupy
> 40% of the retinal sections, while their number and size decrease markedly with age. By 39
weeks of age, less than 10% of the retina appeared to contain patches of disease. With time,
the irregular waviness of the vitreal aspect of the ONL disappeared (compare Figure 9 A1 with
Figure 9 A2), but a substantial thinning was noted. At 39 weeks of age the ONL thickness
(Superior: 36 ± 1 μm; Inferior: 38 ± 1 μm) was reduced to about 44–57% of that measured at
3.9 weeks of age (Superior: 82 ± 4 μm; Inferior: 67 ± 2 μm) (Figure 9 C). Further reduction in
ONL thickness in a 10.3 year-old carrier suggests that rare events of photoreceptor cell loss
persist beyond the 39 week time-point (Figure 9 C).
Immunohistochemistry confirmed these results by showing that in animals older than 26 weeks
of age there was a significant decrease in the number and size of the patches of rod opsin
mislocalization (compare Figure 3 B1 with Figure 3 A1). It also confirmed that the ONL was
thinner but appeared more uniform in older animals (compare Figure 3 B2 with Figure 3 A2).
In older animals, the cone mosaic remained irregular and focal areas of increased cone density
frequently could be found (Figure 4 D1). As early as 12 weeks of age, some of these high cone
density patches were characterized by the clumping of the cell somas, which often resulted in
multiple layers of cones in the ONL (Figure 4 D2–3).
In the inner retina, the number of patches of dendritic retraction followed a similar time course
as that of the patches of rod opsin mislocalization. By 39 weeks of age, these had become very
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rare and the vast majority of the bipolar cells had a normal appearance (compare Figure 6 A2
with Figure 6 A1).
No such remodeling events of the retinal mosaic were seen in young XLPRA1 carriers that
express a later onset and more progressive form of disease.
DISCUSSION
A single report on the use of multifocal electroretinography in carriers of XLRP has shown
that these patients experience a mosaic pattern of retinal dysfunction.26 A similar multifocal
pattern of disease has been confirmed by several histological observations of retinas from older
heterozygotes.16, 18–20 The current study examined the retinas in carriers of two canine models
of RPGR-XLRP, and showed significant changes (summarized in Table 5) in the appearance
of the retinal mosaic as a function of age, particularly in the early onset model. These
remodeling events suggest that the young adult canine retina retains some degree of
morphologic plasticity.
In carriers of XLPRA2, the time of disease onset was similar to that previously reported in
affected animals (~4–5 weeks of age), and was also followed by a burst of rod cell death at 6–
7 weeks of age. This further confirms our conclusion23 that a model of constant or exponentially
decreasing risk of cell death27 does not apply to the kinetics of photoreceptor degeneration in
XLPRA2.
Surprisingly, the peak value of TUNEL-positive cells in heterozygotes was very close to that
found in affected animals (female homozygotes and male hemizygotes), both in timing and
amplitude. In the context of random X-chromosome inactivation, we expected this value to be
about 50 % of that found in affected dogs. This finding may, therefore, reflect the occurrence
of primary skewed X-inactivation, a process that has been implicated in female carriers with
X-linked mental retardation disorders and hemophilia A (For review see 28). A noteworthy
observation is that counts of TUNEL–positive cells in affected and carrier animals were similar
but only at the time of occurrence of the peak of cell death. Indeed, at later time-points, values
in carriers were ~ 50% of that reported in affected dogs. Thus, an alternative explanation could
be that “mutant” photoreceptors undergoing degeneration may cause, through a bystander
effect, the death of neighboring “normal” photoreceptors that are expressing the wild type
allele. Such a non cell-autonomous mechanism of degeneration has been suggested to occur
in the chimeric retina of a transgenic mouse line expressing both wild type and mutant (P347S)
rhodopsin.29 This may be caused through the release of a diffusible apoptosis-promoting factor.
30 If so, during the burst of photoreceptor death, there may be involvement of both intrinsic
(mutation dependent) and extrinsic (toxic/apoptotic inducing factors) mechanisms of cell
death.
When comparing the histopathological patterns between XLPRA1 and XLPRA2 carriers it is
apparent that the mosaic gradually disappears in XLPRA2 between 4.9 and 39 weeks of age,
while it persists, until at least 7.8 years of age, in XLPRA1. This may be correlated with the
time of onset of degeneration in these two diseases (XLPRA2: early onset; XLPRA1 late onset),
and the ability of the retina to undergo a “corrective” remodeling event. We hypothesize that
this may be occurring in the XLPRA2 carrier retina through tangential dispersion of
photoreceptors expressing the wild type RPGR allele into the degenerating patches. Such an
event may only occur during a short time-window that follows photoreceptor maturation in the
dog, and may no longer be present in the “non-plastic” adult retina such as that of a 1.4 year-
old XLPRA1. It is to be determined if post developmental tangential dispersion of
photoreceptors also occurs in human carriers of XLRP as this may have practical implications
for corrective gene therapy. Indeed, if rods and cones have the capacity to move to neighboring
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regions of diseased retina, then there is a risk that a treated region may end up being depleted
of its rescued photoreceptors to the benefit of surrounding non-treated areas. This could have
applications for the treatment of carriers of XLRP by opting for pan-retinal, rather than
localized delivery of the gene therapy construct.
The early onset and rapidly progressing disease that occurs in carriers and affected XLPRA2
dogs (homozygous females and hemizygous males) is thought to result from a toxic gain of
function. The 2 nucleotide deletion (del1084–1085) in RPGRORF15 causes a frameshift that
modifies significantly the amino acid sequence by adding 34 basic residues, increases the
isoelectric point, and prematurely terminates translation 71 amino acids downstream.22 The 5
nucleotide deletion (del 1028–1032) in XLPRA1 introduces a premature stop codon that
truncates the RPGROR15 isoform from its 230 C-terminal amino-acids, and slightly decreases
the isoelectric point.22 The current hypothesis is that this leads to a loss of function of
RPGRORF15, and that this isoform may not be critical for retinal development and maturation.
A similar correlation between disease phenotype and individual mutations in RPGR has been
reported in two mouse models of RPGR-XLRP.31, 32
Besides the difference in the severity and time course of the patchy degeneration, XLPRA1
carriers differed from XLPRA2 carriers by exhibiting variation in disease severity at similar
ages. This has also been found in XLPRA1 affected hemizygous male dogs,24 and is likely
caused by the effect of modifier genes. No such modifiers have been yet identified, however,
candidate genes RPGRIP1, RANBP2, NPM1, PDE6D, NPHP5, and ABCA4 have been
excluded.33
A question that was not addressed in the current study is whether the remodeling of the
cytoarchitecture of the carrier retina is paralleled by some functional plasticity. By 39 weeks
of age, despite a loss of ~ 50 % of rods, the lamination of the ONL and the morphology of rod
bipolar cells appear to have recovered from the earlier phase of multifocal degeneration. This
potentially suggests that rewiring of second order neurons to surviving (non-mutant)
photoreceptors can occur. Assessing whether structural recovery leads to a period of improved
retinal function is a worthwhile subject for future investigation.
Several immunohistochemical and morphologic alterations observed in both the XLPRA1 and
XLPRA2 carrier dogs have also been reported in human patients.34, 35 This includes the
mislocalization of rod and cone opsins16, 19, 20 which may underline the putative role of the
RPGRORF15 isoform in trafficking proteins from the IS to the OS. Double fluorescent IHC
showed that mislocalization of rod and cone opsins occurred within the same patch of disease.
This finding was unexpected since, during retinal development, rods and cones that are clonally
derived from the same photoreceptor progenitor cell have a different pattern of dispersion.
Rods get distributed along a radial column while cones are tangentially dispersed.36, 37 The
mislocalization of cone and rod opsins within a same patch could be explained by a defective
developmental tangential dispersion of cones expressing the mutant RPGR allele.
Alternatively, cone opsin mislocalization may be the consequence of a toxic bystander effect
of the surrounding “mutant” rods on cones that express the wild type RPGR allele. The lack
of an antibody raised against the mutant canine RPGR isoforms currently precludes us from
further investigating this question.
Another common finding that was observed in RPGRORF15 carrier dogs and in a human
patient is the focal aggregation of cones.19 This was easily recognized in older animals, and
was often the only remaining histological criteria that could be used to define a patch of disease.
Careful examination of the cone distribution showed an increased density of cones in the
patches of disease as early as 5.9 weeks of age.
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In XLPRA2, a “corrective” remodeling phase follows the initial burst of cell death, and leads
to preserved retinal lamination despite a loss of approximately 50% of the rods by 39 weeks
of age. However, this event is only transient and topographically restricted as large regions of
degeneration/atrophy are found in the peripheral and mid-peripheral retina of older animals.
A similar topographical distribution has been described in a human carrier.19 Several
mechanisms that are not mutually exclusive could explain this persistent loss of photoreceptors,
and its regional predilection. It has recently been reported that in human fibroblasts at least
15% of all X-linked genes can escape random X chromosome inactivation.38 This secondary
skewing of X inactivation has been shown to be associated with aging, although it is likely to
be species-, tissue- and locus- specific.39, 40 Thus, it is possible that in older carriers of
XLPRA2, reactivation of the silenced mutant RPGR allele may lead to a second wave of
photoreceptor death. Another potential explanation is that there may be a minimal number of
rows of photoreceptors necessary to sustain viability of these cells. If such is the case, then
gradual thinning of the ONL throughout the retinal surface is bound to have a more severe
impact on peripheral regions where the ONL is several rows of ONL thinner than centrally.
Finally, this late phase of peripheral degeneration could potentially also be explained by the
generation of new photoreceptors from progenitor cells located at the retinal margin. Several
reports have suggested that this mechanism of photoreceptor renewal may not be limited to
fish, amphibians and birds, but also may be found in mammals.41 If this is the case in the canine
retina, then newly formed photoreceptors expressing the mutant RPGR allele would not only
undergo cell death but could also cause a detrimental bystander effect on “non-mutant”
photoreceptors located in the peripheral retina.
A significant finding of this study is that the morphologic appearance of the retinal mosaic
changes with time and, as a consequence, so do the histological criteria used to define patches
of degeneration. This was clearly observed in XLPRA2, and may also occur in human carriers
of early onset forms of XLRP. The clinical implication of the remodeling events that occur in
the carrier retina is that, depending on the stage of the disease, it may be challenging to diagnose,
both in animal models and human patients, the mosaic pattern via in vivo imaging techniques
such as optimal coherence tomography. In the case of XLPRA2, OCT imaging in a 5.9 week-
old carrier would potentially identify foci of increased and decreased ONL thickness
corresponding respectively to patches of diseased and normal retina. On the other hand,
examination at later stages would not show any mosaicism and would likely reveal either
normal retinal lamination with generalized and uniform thinning of the ONL (e.g. 39 weeks
of age), or prominent and extended retinal thinning with loss of lamination in the peripheral
retina of much older animals (e.g. 10.3 years of age).
In summary, characterization of the morphological changes that occur in the carrier retina of
two canine models of XLRP has established that prominent remodeling events occur
throughout the course of the disease, and has demonstrated that the retinal mosaic shows a
dynamic and evolving response pattern. It also supports the evidence that heterozygotes for
RPGR-XLRP mutations may experience severe visual impairment.19, 42 These results provide
new insight to gene therapy approaches that can be used in both affected and carrier retinas.
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Figure 1.
Retinal morphology in carriers of XLPRA2. (A) Normal maturation of the retina at 3.9 weeks.
(B) Early patch of outer segment misalignment (below white bar) and ONL thickening in a 4.9
week-old carrier. (C) Prominent foci of outer segment disruption in a 5.9 week-old carrier.
Note the increased thickness of the ONL, decreased cell density and occasional pyknotic figures
(arrows) in these patches. (D1) Multifocal retinal degeneration in a 26.1 week-old carrier of
XLPRA2. Foci of retinal degeneration (arrows) are surrounded by areas of normal retinal
morphology. (D2) High magnification of a patch of retinal degeneration. Note the misalignment
and loss of photoreceptor outer segments, the shortening and broadening of the inner segments,
and the decrease in cell density in the ONL. (D3) High magnification at the transition zone of
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a patch of retinal disease. Note the progressive disorganization of the inner and outer segments,
and the decrease in chromatin compaction of the rods as one moves from a normal to a diseased
area. (E1–3) Retinal disease in a 10.3 year-old carrier of XLPRA2. (E1) Despite a reduction in
ONL thickness (approx 5–6 nuclei thick) in the central region, the retinal morphology appears
well preserved in comparison to the severe retinal degeneration and complete retinal atrophy
observed, respectively, in the mid-peripheral (E2) and peripheral (E3) regions. (Epoxy resin,
1 μm sections) Scale bars: (A–C, E1–3) 20 μm; (D1) 80 μm. Abbreviations: ONL = outer nuclear
layer; INL = inner nuclear layer; GCL = ganglion cell layer.
Beltran et al. Page 14
Invest Ophthalmol Vis Sci. Author manuscript; available in PMC 2009 August 1.
Figure 2.
Retinal morphology in carriers of XLPRA1. (A1–3) H&E stained retinal cryosections along the
superior meridian of a 24 week-old carrier of XLPRA1. No morphologic abnormalities are
detected at this age in the central (A1), mid-peripheral (A2), and peripheral (A3) regions.
(B1–3) Epoxy resin retinal section of a 1.4 year-old carrier of XLPRA1. (B1) Focal patches
(arrows) of retinal degeneration are found throughout the retina. In these areas, there is a loss
of OS, shortening and broadening of IS and a decrease in ONL cell density (B3) and contrast
with surrounding areas (B2) that have a better preserved morphology. (C1–3) Epoxy resin retinal
section of a 7.9 year-old carrier of XLPRA1. (C1) A generalized thinning of the ONL is seen
throughout the retina, yet remaining photoreceptors maintain their normal IS and OS
(asterisks). (C2) Focal area of severe ONL thinning. (C3) Higher magnification of C2 insert.
In this foci note the increased number of cone IS and nuclei, and the reduced density of rods.
Scale bars: (B2–3) 10 μm; (A1–3, C1–2) 20 μm; (B1, C3) 40 μm.
Abbreviations: OS = outer segments; IS = inner segments; ONL = outer nuclear layer; INL =
inner nuclear layer; GCL = ganglion cell layer.
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Figure 3.
Disease and remodeling of the rod photoreceptor mosaic in carriers of XLPRA2. (A1–2) Double
fluorescence immunohistochemistry in a 4.9 week-old XLPRA2 carrier shows numerous
patches of rod opsin (green) mislocalization to the inner segments and ONL but no
abnormalities in cone arrestin labeling (red) (A1). Co-labeling with DAPI nuclear stain (blue)
shows that patches of rod opsin mislocalization and rod neurite sprouting (see arrow in insert)
occur in areas of ONL thickening (A2). Double fluorescence immunohistochemistry in a 39
week-old XLPRA2 carrier shows a single patch of rod opsin (green) mislocalization to the inner
segments and persistent normal expression of cone arrestin (B1). DAPI nuclear stain shows
that the overall ONL thickness is reduced (B2). The inner margin of the ONL is less wavy than
at earlier ages. However persistent focal regions of ONL thickening are seen at the sites of rod
opsin mislocalization (B2). Rod opsin and DAPI labeling in a 5.9 week-old XLPRA2 carrier
imaged by confocal microscopy (maximal projection reconstituted image) (C1). Note the
disorganized OS (arrowheads) in the patches of opsin mislocalization and ONL thickening,
which contrast with the aligned rod OS (arrows) in adjacent areas of non-diseased retina. Insert
seen in C1 is shown as a single plane image at higher magnification in (C2). Scale bars A1–2,
B1–2: 40 μm; C1: 20 μm. Abbreviations: ONL = outer nuclear layer; OS = outer segments.
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Figure 4.
Disease and remodeling of the cone photoreceptor mosaic in carriers of XLPRA2. Double
fluorescence immunohistochemistry in a 4.9 week-old XLPRA2 carrier shows M/L opsin
mislocalization to the inner segments, ONL and cone pedicle (A1) in the same patches where
rod opsin is mislocalized (see asterisks) (A2). (Note 1: the labeling of the inner retina with the
M/L opsin antibody is not specific. Note 2: the yellow labeling seen in the cone outer segments
is the result of a post-acquisition increase in the green signal of the overlay image to improve
visualization of the rod opsin mislocalization, and does not represent co-localization). In a 5.9
week-old XLPRA2 carrier, faint S opsin mislocalization to the inner segments, and ONL is seen
in some cones (arrows) (B1). These cones are located within patches of rod opsin
mislocalization (B2). Immunolabeling in a 5.9 week-old XLPRA2 carrier show an increased
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density in M/L cones in the patches of rod and M/L opsin mislocalization (C1–3). (D1) Plastic
embedded retinal section of a 26.1 week-old XLPRA2 carrier showing focal accumulation of
large euchromatic nuclei resembling that of cones in an area of rod loss. (D2–3) Double
fluorescence IHC in a 39 week-old XLPRA2 carrier showing increased density of cones that
can either be distributed in a monolayer (D2) or clumped together (D3). Note that there is no
rod opsin mislocalization in the patches of increased cone density. Scale bars : (D1) 10 μm;
(A1–2, B1–2, C2–3, D2–3) 20 μm; (C1) 40 μm. Abbreviations: ONL = outer nuclear layer.
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Figure 5.
Focal invasion of the subretinal layer by phagocytic cells in carriers of XLPRA2 (A) Plastic
embedded retinal section of a 26.1 week-old XLPRA2 dog showing a phagocytic cell in the
subretinal space overlying a patch of degeneration. Note the multiple cytoplasmic inclusions
suggestive of phagocytized rod disc material. (B) Double fluorescent IHC in this same animal
labels shows that these cells are labeled with CD18 but not with RPE65 antibodies. This
confirms their macrophage origin. Scale bar: 10 μm. Abbreviations: ONL = outer nuclear layer.
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Figure 6.
Disease and remodeling of the inner retinal mosaic in carriers of XLPRA2 at 7.9 and 39 weeks
of age. Double fluorescence IHC in a 7.9 week-old XLPRA2 carrier shows focal dendritic
retraction of rod bipolar cells (yellow) beneath the patches of rod opsin mislocalization
(asterisks) (A1). Absence of rod bipolar dendritic retraction is noted in the 39 week-old
XLPRA2 carrier (A2). (B1–2) GFAP immunohistochemistry in a 7.9 week-old XLPRA2 carrier
shows patchy labeling of the radial extensions of reactive Müller cells (B1). Double IHC
confirms that these GFAP labeled radial extensions occur in Müller cells located beneath the
larger patches of rod opsin mislocalization (B2). Scale bars: (A1–2) 20 μm; (B1–2) 40 μm.
Abbreviations: ONL = outer nuclear layer; INL = inner nuclear layer.
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Figure 7.
Photoreceptor mosaic in the XLPRA1 carrier. (A1–2) Double fluorescence
immunohistochemistry in a 24 week-old XLPRA1 carrier shows numerous patches of rod opsin
(green) mislocalization to the inner segments and ONL (asterisks), but no abnormalities in cone
arrestin labeling (red) (A1). Co-labeling with DAPI nuclear stain (blue) shows patches of rod
opsin mislocalization and rod neurite sprouting (see arrows) (A2).(B1–2) Double fluorescence
immunohistochemistry in a 24 week-old XLPRA1 carrier shows M/L opsin mislocalization to
the inner segments, ONL and cone pedicle (B1) in the same patches where rod opsin is
mislocalized (B2). Note that M/L opsin labeling of the inner nuclear layer and ganglion cell
layer is non-specific. Scale bars: (A1–2) 20 μm; (B1–2) 40 μm. Abbreviations: ONL = outer
nuclear layer.
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Figure 8.
Photoreceptor cell death in carriers of XLPRA. (A) Kinetics of photoreceptor cell death in the
superior meridian of XLPRA2 carriers. The insert shows previously published (Beltran et al,
IOVS, 2006) kinetics of cell death in affected XLPRA2 dogs. (B) TUNEL labeling of rod nuclei
(arrows) in a 4.9 week-old XLPRA2 carrier is seen exclusively in the patches of rod opsin
mislocalization. (C) Single TUNEL-labeled rod in a 24 week-old XLPRA1 carrier is located
in a patch of rod opsin mislocalization. Abbreviations: ONL = outer nuclear layer.
Beltran et al. Page 22
Invest Ophthalmol Vis Sci. Author manuscript; available in PMC 2009 August 1.
Figure 9.
Remodeling of the retinal mosaic in carriers of XLPRA2. (A1) Numerous foci of retinal disease
(horizontal black bars) occupy a significant proportion of the retinal length as seen here in the
mid-peripheral region of the superior retina of a 5.9 week-old carrier of XLPRA2. (A2)
Infrequent and small foci of retinal disease are found at later ages as illustrated here in the mid-
peripheral region of the superior retina of a 39 week-old carrier of XLPRA2. (B) Percentage
(mean ± SD) of the total retinal length along the superior and inferior meridians that is occupied
by foci of retinal disease in carriers of XLPRA2 of different ages. (C) Mean (±SD) ONL
thickness in the mid-peripheral region of the superior and inferior meridians in XLPRA2
carriers of different ages. Note that ONL thickness was measured in areas between patches of
disease. Scale bars: 10 μm.
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Table 1
List of dogs used for the morphologic, TUNEL, and immunohistochemistry
studies.
ID Age Morphology TUNEL IHC
XLPRA2 carrier
 Z277 3.9 weeks EPON + +
 Z278 4.9 weeks EPON + +
 Z279 5.9 weeks EPON + +
 Z274 7.1 weeks OCT + +
 Z280 7.9 weeks OCT + +
 Z225 12 weeks EPON + +
 Z184 26.1 weeks EPON + +
 Z199 39 weeks EPON + +
 Z87 8.8 Years OCT
 Z24 10.3 Years EPON
XLPRA1 carrier
 H408 20 weeks OCT + +
 H414 24 weeks OCT + +
 H237 (40)* 1.4 Year EPON
 H6 (3)* 3.5 Years EPON
 H74 (18)* 3.8 Years EPON
 H43 (8)* 4.9 Years EPON
 H44 (7)* 5.7 Years EPON
 H25 (4)* 6 Years EPON
 H4 (2)* 7.8 Years EPON
Morphologic assessment was done either on epoxy resin (EPON) embedded sections or on OCT (OCT) embedded cryosections.
IHC: immunohistochemistry; +: done;
*
Number in parenthesis corresponds to identification used in Zeiss et al. IOVS (1999).
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Table 4
Central and peripheral ONL thickness (mean number of rows of ONL nuclei/site) along the superior meridian of XLP
RA1 carrier retinas.
ID Age Central peripheral
XLPRA1 carrier
H408 20 weeks 9 7
H414 24 weeks 9 6–7
H237 1.4 years 9 3–4
H6 3.5 Years 9 3
H74 3.8 years 5 0
H43 4.9 years 6–7 3–4
H44 5.7 years 5 2–3
H25 6 Years 5 1–2
H4 7.8 Years 5 4–5
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